Keywords: Multiple myeloma, Market forecasts, Decision Resourcs, Celgene, Revlimid, Takeda, Johnson & Johnson, Velcade
Multiple myeloma drug market forecast to reach $7.2 billion in 2021
Article | 03 October 2012
The multiple myeloma drug market will experience significant growth, increasing from $4.4 billion in 2011 to $7.2 billion in 2021 (a 5.2% annual growth) in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
